Business
Pharmaceutical Industry Updates
Eli Lilly announced an access program for its unapproved obesity drug retatrutide. Meanwhile, Gilead secured a court victory in a related legal dispute.
Coverage timeline — 9 articles
STAT News
Smaller biotechs move to negotiate with White House, medicine's trust gap, and other biotech news from The Readout
2026-04-03 13:39 UTC
STAT News
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
2026-04-03 13:42 UTC
STAT News
Scientists whose work led to powerful obesity drugs like Zepbound are now suggesting targeting the GLP-1 hormone is not necessary for effective weight loss
2026-04-17 13:07 UTC
STAT News
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
2026-04-17 13:09 UTC
STAT News
From new hires to departures and promotions, here are the latest comings and goings in the pharmaceutical industry.
2026-03-20 14:53 UTC
STAT News
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
2026-04-24 15:53 UTC
STAT News
Lilly disclosed new data that provide more details on the safety and tolerability of its next-generation obesity drug retatrutide
2026-06-08 13:28 UTC
STAT News
Eli Lilly confirmed that it will allow more patients to apply for early access to retatrutide, an unapproved obesity drug
2026-08-04 13:11 UTC
CNBC
Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots.
2026-03-18 17:17 UTC